Mesenchymal chondrosarcoma of the maxilla by Bottrill, I. D. et al.
The Journal of Laryngology and Otology
September 1994. Vol. 108,'pp. 785-787
Mesenchymal chondrosarcoma of the maxilla
I. D. BOTTRILL*, S. WOOD*, P. BARRETT-LEE1\ D. J. HOWARD*
Abstract
We report, to our knowledge, the 1 Oth recorded case of mesenchymal chondrosarcoma (MC) occurring in the maxilla. Our
case is the youngest person reported with a tumour in this location. The prognosis for cure is poor with a high incidence of
local recurrence as well as metastases. Treatment is based on radical surgery. Radiotherapy and chemotherapy have a
adjuvant role but additional experience with this tumour is required to define the most efficacious treatment.
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Case report
A 15-year-old girl presented to our clinic with a 10-month
history of bilateral nasal obstruction. In addition she had noticed
a watery rhinorrhoea and slight epistaxis. She had no significant
past medical history.
On examination she looked well, there was no evidence of
neck lymphadenopathy. Nasal examination revealed copious
FIG. 1
Coronal CT scan of the head showing an extensive tumour
occupying the nasal cavity and right antrum. Note the bony erosion
of the hard palate and speckled calcification.
FIG. 2
Lateral X-ray of the facial skeleton showing a radiolucent region in
the hard palate.
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TABLE I
RECORDED CASES OF MESENCHYMAL CHONDROSARCOMA (MC) OF THE UPPER JAW
Reference Age (years) Sex Presenting symptoms Duration8 Treatment Status"
Bottrill etal. (1994)
Hiratsuka and Kohama (1991)
Salmoero/. (1988)
Bloch<?/a/. (1979)
Salvador et al. (1971)
Dahlin and Henderson (1962)
15
62
68
18
24
46
30
23
F
M
M
M
F
F
M
F
Nasal Blockage
Epistaxis
Swelling
Swelling
Pain
Swelling
Loose teeth
Nasal Blockage
Epistaxis
Swelling
Swelling
Swelling
10/12
•>
1
2
7
1
7
9
Maxillectomy
Radiotherapy
Chemotherapy
Maxillectomy
Orbital recurrence;
Chemotherapy
'Excision'
Radiotherapy - poor
response
Maxillectomy
Orbital exenteration
Maxillectomy
Radiotherapy
Local recurrence at
15 years
Maxillectomy
Retroperitonial
metastases at
8.5 years
Local recurrence at
9 years
Maxillectomy
Radium therapy
Curettage + radium
Local recurrence at
3 years
Roentgen therapy
Lung metastases at
22 years
Right pneumonectomy
Breast metastases at
22 years
Vulva, pelvis and scalp
metastases at
23 years
Dead: 10 months
Dead: 47 months
Patient lost to
follow-up
Alive: disease-free at
7 years
Not stated
Dead: 9.5 years
Dead: 6 years "of
cancer'
Dead: 23 years
"The duration the symptoms were present prior to the first consultation (years).
"The time quoted is the duration of survival from first presentation.
quantities of mucus in both nasal cavities and a mass in the right
nasal cavity. Immorally there was a large mass occupying two
thirds of the hard palate. It had a lobulated appearance, was firm
and nontender. The overlying mucosa was normal and the cra-
nial nerves were intact.
A CT scan was carried out (Figure 1) showing a large mass in
the lower anterior part of the right antrum which appeared to be
arising from the upper alveolus which was extensively eroded.
The mass contained considerable peripheral calcification but
showed minimal enhancement. It extended downwards into the
mouth and across the midline into the left nasal cavity. The
appearance suggested an odontogenic type of tumour.
The patient was admitted for further investigations. All rou-
tine haematological and biochemical investigations and a chest
X-ray were normal. A biopsy was performed and the tumour was
reported as a haemangiopericytoma (HPC). She therefore under-
went a right maxillectomy via a mid-facial degloving approach.
The tumour had breached the posterior wall of the maxilla and
was present in the pterygopalatine fissure on the right. Post-
operatively she made a rapid recovery. The diagnosis was
revised on histological assessment of the operative specimen to
mesenchymal chondrosarcoma.
In view of the extent of the disease she was given a course of
post-operative radical radiotherapy and combination chemo-
therapy. The radiotherapy was given to the right side of the face
using a wedged pair of fields to a total dose of 60 Gy in seven
weeks. It was planned to give her six courses of cisplatin (100
mg/nr: one four hourly infusion) and adriamycin (25 mg/m2:
three doses intravenously over three days) at three weekly inter-
vals. She required several admissions for neutropaenic sepsis
which prolonged the interval between courses. Ten days after her
fifth course of chemotherapy she was admitted with a further
prolonged episode of neutropaenic sepsis. She was treated with
intravenous antibiotics and after seven days the neutrophil count
recovered and her clinical condition stabilized. However, despite
a normal neutrophil count, she became pyrexial again and blood
TABLE II
CLINICAL COURSE OF PATIENTS WITH MESENCHYMAL CHONDROSARCOMA (MC) AFTER VARYING TREATMENT MODALITIES (AFTER NAKASHIMA
ETAL., 1986)
No. of patients Primary modality No. with recurrence" No. alive" No. dead from MC"
41 Intralesional excision
22 Wide local excision
7 Primary radiotherapy and/or chemotherapy
37 Surgery and radiotherapy and/or chemotherapy
33
(2.9 years)
9
(3.6 years)
7
9
(5
(7
12
.4 years)
16
.8 years)
0
27
(5.5 years)
6
(5.9 years)
6
(2.2 years)
30
"Numbers in brackets refer to the mean duration of survival from initial treatment.
CLINICAL RECORDS 787
cultures grew Candida spp. Antifungal therapy was started but
unfortunately her condition rapidly deteriorated despite vigor-
ous cardiovascular and respiratory support and she died three
weeks following her last admission. She had survived 10 months
after her initial presentation. A postmortem was performed
which confirmed septicaemia and adult respiratory distress syn-
drome as the cause of death but showed no evidence of local or
distant recurrence.
Discussion
Mesenchymal chondrosarcoma is a very rare but characteristic
malignant tumour first described by Lichtenstein and Bernstein
(1959). Mesenchymal chondrosarcoma can occur in both
osseous and extra-osseous sites in a ratio of 2:1 (Nakashima
et al., 1986). The total number of tumours recorded in the world
literature for all sites was 51 by 1971 (Salvador et al., 1971);
more recent reviews report numbers in excess of 160 (Williams
et al., 1987). In the head and neck region the mandible is the
commonest site of bony origin for the tumour. However there
have only been nine cases reported arising from the maxilla;
seven in a review of the literature by Nakashima et al. (1986) and
two further case reports, one by Hiratsuka and Kohama (1991)
and the other by Salmo et al. (1988).
Mesenchymal chondrosarcoma (MC) of the jaws has the
highest incidence in the second and third decades. The sex inci-
dence is approximately equal.
Radiographically the lesions show up as areas of radiolucency
which may be well or poorly demarcated (Figure 2). Approxi-
mately 50 per cent may show diffuse calcification (Huvos et al.,
1983). Macroscopically these tumours are soft to firm and grey-
white to red/tan and may contain calcific deposits. As a con-
sequence of this a gritty texture may be noted.
The histopathological pattern of these tumours demonstrates a
bimorphic pattern composed of abundant sheets or clusters of
highly undifferentiated mesenchymal cells, with prominent
nuclei and scanty cytoplasm, interspersed with small islands of
well differentiated cartilaginous tissue in which calcification and
areas of metaplastic bone formation may be observed. The histo-
logical picture of these tumours may be confused at first sight
with haemangiopericytoma (HPC), especially if a biopsy is
taken that does not show areas of cartilage formation as in this
case and in other cases reported in the literature (Bloch et al.,
1979; Fu and Perzin, 1974). Immunohistochemical studies have
demonstrated that the mesenchyme resembles that of embryonic
cartilage (Swanson et al., 1990). Histological grading is stated to
be of little clinical significance and all mesenchymal chondro-
sarcoma tumours are considered to be high grade. If only the cel-
lular area is included in the biopsy then the differential lies
between MC, HPC, solid rhabdomyosarcoma and synovial
sarcoma.
Table I shows data recorded from mesenchymal chondrosar-
coma arising in the maxilla. The predominant presenting symp-
tom is swelling, more rarely pain and epistaxis may occur.
Neurological compression may be the presenting symptom in
tumours arising from other sites. In their review, Nakashima
et al. (1986) reported that the symptoms had been present from
four days to seven years at the first consultation and three out of
111 patients had metastases at presentation.
Treatment for this condition is based on experience with rela-
tively few cases and no one centre has sufficient experience to
produce any form of scientific proposal. The basis of the treat-
ment is one of initial radical surgery with, or without, adjuvant
radiotherapy and/or chemotherapy. There is little evidence that
the later improves the prognosis significantly. Nakashima et al.
(1986) reviewed the outcome of patients treated in each of four
broad groups. The numbers in each do not allow statistical
analysis and the patients have a variety of tumour locations and
'stages'. Despite these flaws Table II demonstrates that radio-
therapy and/or chemotherapy alone appear to be of little benefit.
In addition there is no convincing advantage to be gained using
any of the other treatment modalities.
Patients may succumb relatively quickly from their disease or
may remain well for many years. Of 78 patients with adequate
follow-up data the duration from primary treatment to first met-
astasis varied from 0 to 22 years with the lung being the most fre-
quent site. However local recurrence usually occurred before
distant metastases (Nakashima et al., 1986).
The prognosis for mesenchymal chondrosarcoma is poor, but
the clinical course may be protracted. Huvos et al. (1983) found
a five-year survival rate of 42 per cent and a 10-year one of 28 per
cent. Therefore prolonged follow-up is required.
Conclusion
In view of the rarity of this condition it would be valuable to
collate data in one central registry. This would encourage
continuous follow-up and monitoring of treatment protocols and
might also allow for unified trials of therapy.
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